JP2015529234A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529234A5
JP2015529234A5 JP2015532437A JP2015532437A JP2015529234A5 JP 2015529234 A5 JP2015529234 A5 JP 2015529234A5 JP 2015532437 A JP2015532437 A JP 2015532437A JP 2015532437 A JP2015532437 A JP 2015532437A JP 2015529234 A5 JP2015529234 A5 JP 2015529234A5
Authority
JP
Japan
Prior art keywords
combination
compound
regorafenib
acetylsalicylic acid
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532437A
Other languages
English (en)
Japanese (ja)
Other versions
JP6294888B2 (ja
JP2015529234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/069735 external-priority patent/WO2014048881A1/en
Publication of JP2015529234A publication Critical patent/JP2015529234A/ja
Publication of JP2015529234A5 publication Critical patent/JP2015529234A5/ja
Application granted granted Critical
Publication of JP6294888B2 publication Critical patent/JP6294888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532437A 2012-09-25 2013-09-23 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ Active JP6294888B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852.6 2012-09-25
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (3)

Publication Number Publication Date
JP2015529234A JP2015529234A (ja) 2015-10-05
JP2015529234A5 true JP2015529234A5 (US20040106767A1-20040603-C00005.png) 2016-11-10
JP6294888B2 JP6294888B2 (ja) 2018-03-14

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015532437A Active JP6294888B2 (ja) 2012-09-25 2013-09-23 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ

Country Status (29)

Country Link
US (1) US10898500B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP2900269B1 (US20040106767A1-20040603-C00005.png)
JP (1) JP6294888B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR102210575B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN104994876A (US20040106767A1-20040603-C00005.png)
AU (1) AU2013322854B2 (US20040106767A1-20040603-C00005.png)
BR (1) BR112015006686B1 (US20040106767A1-20040603-C00005.png)
CA (1) CA2885688C (US20040106767A1-20040603-C00005.png)
CL (1) CL2015000744A1 (US20040106767A1-20040603-C00005.png)
CY (1) CY1120939T1 (US20040106767A1-20040603-C00005.png)
DK (1) DK2900269T3 (US20040106767A1-20040603-C00005.png)
EA (1) EA032023B1 (US20040106767A1-20040603-C00005.png)
ES (1) ES2687985T3 (US20040106767A1-20040603-C00005.png)
HK (1) HK1214169A1 (US20040106767A1-20040603-C00005.png)
HR (1) HRP20181462T1 (US20040106767A1-20040603-C00005.png)
HU (1) HUE039878T2 (US20040106767A1-20040603-C00005.png)
IL (1) IL237690B (US20040106767A1-20040603-C00005.png)
LT (1) LT2900269T (US20040106767A1-20040603-C00005.png)
MX (1) MX357035B (US20040106767A1-20040603-C00005.png)
MY (1) MY183969A (US20040106767A1-20040603-C00005.png)
NZ (1) NZ705860A (US20040106767A1-20040603-C00005.png)
PH (1) PH12015500587A1 (US20040106767A1-20040603-C00005.png)
PL (1) PL2900269T3 (US20040106767A1-20040603-C00005.png)
PT (1) PT2900269T (US20040106767A1-20040603-C00005.png)
RS (1) RS57875B1 (US20040106767A1-20040603-C00005.png)
SG (2) SG10201702356VA (US20040106767A1-20040603-C00005.png)
SI (1) SI2900269T1 (US20040106767A1-20040603-C00005.png)
WO (1) WO2014048881A1 (US20040106767A1-20040603-C00005.png)
ZA (1) ZA201502840B (US20040106767A1-20040603-C00005.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
LT2900669T (lt) 2012-09-25 2019-11-11 Hoffmann La Roche Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CA2923523A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
UA118582C2 (uk) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa)
CN103923001B (zh) * 2014-04-30 2016-02-10 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2017037146A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MX2018015965A (es) * 2016-06-28 2019-05-22 Asamedic As Composicion de dos componentes.
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
AU2018276273B2 (en) 2017-06-02 2023-12-21 Bayer Healthcare Llc Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373940A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
CA2628881A1 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Similar Documents

Publication Publication Date Title
JP2015529234A5 (US20040106767A1-20040603-C00005.png)
JP2014509659A5 (US20040106767A1-20040603-C00005.png)
ES2745471T3 (es) Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
JP2012255026A5 (US20040106767A1-20040603-C00005.png)
JP2014512354A5 (US20040106767A1-20040603-C00005.png)
JP2015511609A5 (US20040106767A1-20040603-C00005.png)
JP2016534063A5 (US20040106767A1-20040603-C00005.png)
JP2015536986A5 (US20040106767A1-20040603-C00005.png)
RU2016141569A (ru) Комбинации
JP2013518107A5 (US20040106767A1-20040603-C00005.png)
RU2015121367A (ru) Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JP2013522326A5 (US20040106767A1-20040603-C00005.png)
JP2014512355A5 (US20040106767A1-20040603-C00005.png)
JP2016528162A5 (US20040106767A1-20040603-C00005.png)
JP2015501783A5 (US20040106767A1-20040603-C00005.png)
JP2015038135A5 (US20040106767A1-20040603-C00005.png)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ714963A (en) Compositions and methods for treating anemia
JP2013541595A5 (US20040106767A1-20040603-C00005.png)
JP2015512398A5 (US20040106767A1-20040603-C00005.png)
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
HRP20201681T1 (hr) Inhibitor aurora a kinaze
MX342062B (es) Composicion farmaceutica para administracion oral.
NZ628392A (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease